Efficacy and Safety of Polymer-free Amphilimus-eluting Stent According to the Diabetes
Study Details
Study Description
Brief Summary
Drug-eluting stents (DES) have been found to reduce the rate of stent restenosis compared to bare metal stents (BMS), but the first generation DES caused an increase in stent thrombosis. The second generation DES, including the Cre8Evo stent, has been designed to address these issues. The Cre8Evo stent is made of cobalt chromium and releases the drug amphilimus into the vessel wall, which is quickly absorbed and then lost, creating a BMS-like form. The Cre8Evo stent does not contain polymers and does not induce an inflammatory response. It inhibits cdk2 and RhoA, reducing the proliferation and migration of vascular smooth muscle cells. In diabetic patients, the Cre8Evo stent showed superior results in suppressing late proliferation compared to conventional DES. The Cre8Evo stent has been found to be safe and effective in clinical studies, and it has a superior effect in the clinical course of diabetic patients compared to other stents. The purpose of the study is to evaluate the effectiveness and safety of the Cre8Evo stent in actual clinical practice, specifically comparing outcomes in patients with and without diabetes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Target lesion failure(Device-oriented composite endpoints) [12 month]
composite of cardiac death, any myocardial infarction not clearly attributatble to a non-target vessel, and clinical indicated target lesion revascularization in patient with DM and non-DM
Secondary Outcome Measures
- patient-oriented composite endpoint [12 month]
composite of all-cause mortality, any myocardial infarction, and any revascularization in patient with DM and non-DM
- Incidence of all-cause mortality [12 month]
Incidence of all-cause mortality in patient with DM and non-DM
- Incidence of all-cause cardiac death [12 month]
Incidence of all-cause cardiac death in patient with DM and non-DM
- Incidence of all-cause non-cardiac death [12 month]
Incidence of all-cause non-cardiac death in patient with DM and non-DM
- Incidence of any myocardial infarction [12 month]
Incidence of any myocardial infarction in patient with DM and non-DM
- Incidence of any myocardial infarction not clearly attributatble to a non-target vessel [12 month]
Incidence of any myocardial infarction not clearly attributatble to a non-target vessel in patient with DM and non-DM
- Incidence of any revascularization [12 month]
Incidence of any revascularization in patient with DM and non-DM
- Incidence of target lesion revascularization [12 month]
Incidence of target lesion revascularization in patient with DM and non-DM
- Incidence of stent thrombosis [12 month]
Incidence of stent thrombosis in patient with DM and non-DM
- Lesion success rate [the day of procedure]
less than 50% of residual stenosis after all procedure in patient with DM and non-DM
- Procedural success rate [1 month]
composite of less than 50% of residual stenosis after all procedure, no in-hospital event including death, MI, revascularization in patient with DM and non-DM
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 19 or older
-
Patients who agreed to the research protocol and clinical follow-up plan, voluntarily decided to participate in this study, and gave written consent to the consent form ③ Patients who underwent coronary angioplasty by inserting Cre8™ or Cre8™ EVO stent for coronary artery disease for a lesion confirmed within the last 1 month
Exclusion Criteria:
-
Patients with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, amphilimus, cobalt chrome, stainless steel nickel, 316L metal, and contrast media If it can be controlled by pheniramine and pheniramine, registration is possible, but if there is known anaphylaxis, it is excluded.)
-
Pregnant women, lactating women, or women of childbearing age who are planning to become pregnant during the study period ③ Patients who are planning surgery to stop antiplatelet drugs within 12 months from registration
-
Patients whose remaining life expectancy is expected to be less than 1 year
-
Patients who visited the hospital due to cardiogenic shock and are predicted to have a low survival rate based on medical judgment ⑥ Subjects participating in medical device randomization research ⑦ Patients who underwent surgery using a stent other than Cre8™/Cre8™ EVO at the time of registration
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Korea University Anam Hospital | Seoul | Korea, Republic of | 136-705 |
Sponsors and Collaborators
- Korea University Anam Hospital
- Diomedical
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CRE8DM